Jim Cramer’s Surprised About US Travel As He Discusses These 18 Stocks

7. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders In Q4 2024: 91

Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. It is a regular feature of Cramer’s morning show. In his previous appearances, the TV host has lamented that China is creating hurdles for Merck & Co., Inc. (NYSE:MRK)’s drugs in the country. Cramer is also a fan of the firm’s CEO Rob Davis. Here are his latest thoughts about Merck & Co., Inc. (NYSE:MRK):

“You know David, this is an earnings season so far where a lot of big ones, that look like they’re just shockingly bad, or disappointing, everyone knew. I mean, Merck reported a quarter, I think we all kind of knew that KEYTRUDA had slown a little bit. we know that there were some GARDASIL problems, WINREVAIR, a drug that they bought, pulmonary arterial hypertension, I thought it was terrific. 280 million. So I think that this is an example where we can just say, oh my god, Merck down almost 40%, I gotta take a hard look at it, Merck’s a good company.”

“You know how people are David, when you get to within a couple of years of a major drug like KEYTRUDA, that is so big. I mean KEYTRUDA by the way, accrued 4%, 7.2 billion. . .and to me, I look at this and I say, look, they’re gonna have a lot of money. And they’ll go do what’s right. Other people look at it and say, Pfizer had a lot of money and what did they do? So you Merck and Pfizer, you have one and two for long time that’s been the great ones. . . I look at Merck and say, the reason why it’s not down, is people just say, it just can’t be that bad at Merck. And I think that that’s actually probably a good sentiment.”